Gabexate Mesylate is a Factor X inhibitor.

Gadodiamide is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Target: OthersGadodiamide(Omniscan) is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Gadodiamide is a contrast medium for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). A recent review takes the question of toxicity caused by loss of gadolinium from the complex. "The challenge for nephrologists includes (a) evidence of transmetallation, such as gadolinium deposits in bone, increased urinary zinc excretion, iron-transferrin dissociation or 'spurious hypocalcemia' in exposed people"。

GAK inhibitor 49 is a potent, selective, ATP-competitive inhibitor of cyclin G-associated kinase (GAK, cell IC50=56 nM) with favourable NAK family selectivity (AAK1, STK16, BMP2K).

Galactose 1-phosphate is an intermediate in the galactose metabolism and nucleotide sugars.

Galactose 1-phosphate Potassium salt is is an intermediate in the galactose metabolism and nucleotide sugars

Galvestine-1 is a small molecule MGDG (monogalactosyldiacylglycerol) synthase inhibitor with IC50 of 10 uM by competing with diacylglycerol binding.

Gamitrinib TPP is a GA mitochondrial matrix inhibitor.

gamma-secretase modulator 3 is a gamma-secretase modulator.

Ganaplacide (KAF156, GNF-156) is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains.

Ganciclovir

Ganirelix is a man-made form of a protein that reduces the amount of certain hormones in the body, including estrogen.

GANT 61(NSC 136476) is a small molecule inhibitor of Gli1 and Gli2.

GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Garcinol (Camboginol) is a potent, natural inhibitor of histone acetyltransferases (HATs) p300 (IC50=7 uM) and PCAF (IC50=5 uM) both in vitro and in vivo.

Gardiquimod trifluoroacetate is a specific TLR7 agonist which can also inhibit HIV-1 reverse transcriptase.

GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3).

GB-83 is a selective, reversible PAR2 (Protease-activated receptor 2) antagonist with IC50 of 2 uM.

Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma.

GBT-440(Voxelotor) is a novel small molecule hemoglobin modifier which increases hemoglobin oxygen affinity.

GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with IC50s of <0.3 μM in the enzyme and cell assay.

GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with IC50 of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

GDC-0068 is a highly selective pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 5 nM, 18 nM and 8 nM, respectively.

GDC-0152 is a potent inhibitor of IAPs; binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively.

GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases.

GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile.

GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP).

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.

Gea 3162 is a potent inhibitor of ADP-induced platelet aggregation in platelet rich plasma (PRP). GEA 3162 stimulates cGMP production in platelets, granulocytes, and polymorphonuclear leukocytes.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.

Gemcitabine Hydrochloride (Gemzar) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(1.216), SARS-COV(4.9

Gemcitabine monophosphate disodium salt, also called GemMP, is a monophosphate derivative of Gemcitabine.

Gemfibrozil (Lopid)

Gemifloxacin mesylate (trade name Factive, Oscient Pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

Genipin

Geniposide

Geniposidic acid

Genistein is a highly specific inhibitor of protein tyrosine kinase (PTK).

Genistin is an isoflavone glycoside found in soy-based products. Can be used as a negative control for the PTK inhibitor Genistein

Gentamycin sulfate (Gentacycol)

Genz-123346 free base is an inhibitor of GL1 synthase that blocks the conversion of ceramide to GL1; IC50 for GM1 inhibition is 14 nM.

Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC50 of 43 μM.

Geranylgeranylacetone can induce expression of HSP70, HSPB8, and HSPB1. Induction of HSP70 expression is protective against the development of various diseases, such as hypoxic/ischemic brain injury, inflammatory bowel disease and spinal and bulbar muscul

Gerfelin is an osteoclastogenesis inhibitor (IC50=61 uM) through the competitive inhibition of glyoxalase I (GLO1) with Ki of 0.15 uM.

Gestodene(SHB 331;WL 70) is a progestogen hormonal contraceptive.

GGTI 2417 is the methyl ester prodrug of GGTI-2418, a highly potent, competitive, and selective inhibitor of GGTase I.

GGTI 2418 (PTX 100) is a highly potent, competitive, and selective peptidomimetic inhibitor of geranylgeranyltransferase I (GGTI) with IC50 of 9.5 nM, displays 5,600-fold selectivity over FTase.

GGTI 2418 sodium (PTX 100) is a highly potent, competitive, and selective peptidomimetic inhibitor of geranylgeranyltransferase I (GGTI) with IC50 of 9.5 nM, displays 5,600-fold selectivity over FTase.

GGTI-2133 is a potent and selective GGTase I inhibitor

GGTI-2147 is a non-thiol peptidomimetic that inhibits GGTase I and blocks geranyl-geranylation of Rap1A (IC50=0.5 uM).

GGTI-286 is a CAAX peptidomimetic that is a potent, cell-permeable, and selective inhibitor of GGTase I with IC50 of 2 uM, 25-fold more potent than FTI-277.

GGTI-286 is a CAAX peptidomimetic, potent, cell-permeable, and selective inhibitor of GGTase I with IC50 of 2 uM, 25-fold more potent than FTI-277.

GGTI-DU40 is highly selective inhibitor for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDA-MB-231 breast cancer cells with GGTI-DU40 inhibited thr

GHRP-2 is a synthetic hexapeptide Growth Hormone Releasing Peptide (GHRP), which acts on the hypothalamus and the pituitary gland to release growth hormone with a slight stimulator effect on Prolactin, ACTH and Cortisol levels.

GI-530159 (ICA-069771) is a novel potent, selective, mechano-sensitive K2P channel (TERK) opener with EC50 of 1 uM for TERK1.

GIBH-130 is a novel inhibitor of neuroinflammation effective in Alzheimer’s disease models.

Gimeracil(Gimestat) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination.

GJ103 is an active analog of the read-through compound GJ072.

GK563 (GK-563) is a potent, selective inhibitor of Ca2+-independent phospholipase A2 (GVIA iPLA2) with IC50 of 1 nM, >20,000-fold selectivity over GIVA cPLA2.

GK921 is a transglutaminase 2 (TGase 2) inhibitor with average GI50 of 0.9 uM in cancer cell lines.

GKI-1 is a Greatwall (GWL) kinase inhibitor with IC50s of 4.9 and 2.5 µM against hGWLFL and hGWL-KinDom, respectively. GKI-1 robustly inhibits ROCK1 with an IC50 of 11 µM, but only weakly affected PKA.

GL-1196 is a PAK4 inhibitor that effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclinD1 pathway and CDK4/6 expression.

Glabrescione B (GlaB) is a small molecule binding to Gli1 zinc finger and impairing Gli1 activity by interfering with Gli1/DNA interaction, inhibits Hh signaling by impairing Gli1 function; inhibits the growth of Hedgehog-dependent tumor cells in vitro and in vivo, inhibits Gli1-dependent growth of cerebellum-derived normal progenitors; inhibits the growth of Gli-dependent medulloblastoma and tumor-derived stem-like cells; inhibits the growth of Gli-dependent basal cell carcinoma in vitro and in vivo.

Glabridin is a bio-available isoflavan isolated from licorice (Glycyrrhiza glabra L.) root extract

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Glimepiride(Amaryl) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.

Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.

Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.

Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.

GLP-1 receptor agonist-1 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1(7-36) is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM.

GLS1 inhibitor is an inhibitor of glutaminase 1

GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations.

Glucokinase activator 1 is a liver-directed glucokinase activator with an EC50 of 34 nM.

Glucosamine (hydrochloride) is a natural product.

Glutaminase C-IN-1 (968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts.

Glycodeoxycholate Sodium is a bile salt.

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.

Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.

Glycopyrronium bromide (CHF 5259) is a peripherally-acting quaternary ammonium antimuscarinic agent with little or no central nervous system activity.

Gly-Pro-pNA is a chromogenic substrate that can be cleaved by the circulating enzyme, dipeptidyl peptidase IV (DPP IV).

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.

GNE 220 (Hydrochloride) is a potent and selective inhibitor of MAP4K4, with an IC50 of 7 nM.

GNE-0439 is a novel potent, selective inhibitor of Nav1.7 channel with IC50 of 0.34 uM, shows high selectivity over Nav1.5 (IC50=38.3 uM).

GNE-049 (GNE049) is a potent, selective, orally available inhibitor of CBP/p300 bromodomain with biochemical IC50 of 1.1/2.3 nM, respectively.

GNE-220 is a potent and selective inhibitor of MAP4K4 with IC50 of 7 nM, also inhibits MINK (MAP4K6), DMPK and KHS1 (MAP4K5) with IC50 of 9 nM, 476 nM and 1,110 nM.

GNE-2861 is a potent, selective group II PAK (PAK4/5/6) inhibitor with IC50 of 7.5/126/36 nM, respectively, shows selectivity over group I PAKs (IC50=5.42/0.97/>10 uM for PAK1/2/3).

GNE-293 is a potent and selective PI3Kδ inhibitor with Ki of 0.47 nM, displays 256, 420, 219-fold selectivity over PI3Kα, PI3Kβ, PI3Kγ, respectively.

GNE-375 is a potent, selective BRD9 inhibitor with IC50 of 5 nM, displays >480-fold selectivity over BRD4, CECR2, and TAF1.

GNE-431 is a potent, selective and noncovalent Btk inhibitor with IC50 of 3.2 nM and 2.5 nM for WT Btk and C481S mutant, respectively.

GNE-616 (GNE616) is a highly potent, metabolically stable, subtype selective inhibitor of Nav1.7 with Ki of 0.79 nM (hNav1.7).

GNE-617 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with IC50 value of 5nM.

GNE-7915 tosylate (GNE7915 tosylate) is a highly potent, selective, and brain-penetrable LRRK2 inhibitor with IC50 of 1.9 nM.

GNE-8324 is a potent and selective NMDA receptor PAM.

GNE-886 is a potent and selective CECR2 bromodomain inhibitor with IC50 of 16 nM.

GNE-955 is a potent pan Pim kinase inhibitor with Kis of 18, 110, 8 nM for Pim1, Pim2, Pim3, respectively.

GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).

GNF-5837 is a potent pan-Trk inhibitor which display antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively).

GNF-6231 is a potent, orally active and selective Porcupine inhibitor with IC50 of 0.8 nM.

GNX-865 is a potent mitochondrial permeability transition pore (mPTP) inhibitor with EC50 of 105 uM (mitochondrial swelling).

GO289 (GO-289, GO 289) is a potent and selective inhibitor of casein kinase 2 (CK2) with IC50 of 7 nM in in vitro kinase assays, shows minor effects on CKIδ and CKIα activity in vitro.

Golgicide A is a potent, highly specific, reversible inhibitor of the cis-Golgi ArfGEF GBF1, inhibits the effect of shiga toxin on protein synthesis with IC50 of 3.3 uM.

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.

Gomisin A has anti-inflammatory, antihypertensive, neuroprotective, and anti-proliferation properties, it induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal tran

GOT1 inhibitor 2c is a first-in-class, non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with IC50 of 8.2 uM..

GPDA(Glycylproline p-nitroanilide tosylate) is the substarate of X-Prolyl dipeptidyl-aminopeptidase in the enzyme assay.

GPR139 agonist AC4 is a novel small molecule GPR139 receptor agonist with EC50 of 220 nM in calcium mobilization assay in CHO-GPR139 cells. .

GPR39 modulator 3 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=5 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.

GPR39 modulator 7 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=20 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.

GPR4 antagonist 3 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. Anti-inflammatory activities.

Gpr52 antagonist E7 (Scabertopin) is a novel Gpr52-specific small molecule antagonist, reduces mutant HTT levels and rescues Huntington's disease-associated phenotypes in cellular and mouse models..

GpTx-1 is a potent, selective, 34-residue peptide antagonist of Nav1.7 sodium channel with IC50 of 10 nM, displays 20- and 1000- fold selectivity over NaV1.4 and NaV1.5..

GR-127935 potent and selective 5-HT1B/1D receptor antagonist with pKi of 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptor.

GR148672X is a specific TGH inhibitor.

GR-64349 is a potent and selective tachykinin NK2 receptor agonist with EC50 of 3.7 nM, displays >1000- and >300-fold selectivity over NK1 and NK3 receptors, respectively..

GR-73632 is a potent and selective tachykinin NK1 receptor agonist with EC50 of 2 nM, promotes differentiation but not survival of rat chromaffin cells in vitro..

Gracillin is a kind of steroidal saponin isolated from the root bark of wild yam Dioscorea nipponica with antitumor agent.

Grape Seed Extract

GRGDSP (TFA) is an integrin inhibitor.

GRL-0617 is a potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 0.6 uM, Ki of 0.49 uM.

GS 462808 is a potent Late INa current inhibitor with IC50 of 1.33 uM.

GS-1 is a close structural analog of GS-5806 that acts an RSV fusion inhibitor.

GS-493 is a novel potent, selective SHP2 inhibitor with IC50 of 71±15 nM in enzyme assay.

GS-6207 (GS6207, GS-CA1) is a potent, selective inhibitor of HIV-1 capsid function with potency and potential to be clinically effective against a broad range of HIV-1 strains..

GS-626510 (GS-6510, GS 6510, GS 626510) is a novel BET family bromodomains inhibitor with Kd of 0.5-2.8 nM for BRD2/3/4, and BRDT.

GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate.

GS-7340(Tenofovir alafenamide) is a prodrug of tenofovir (TFV) that more efficiently delivers TFV into lymphoid cells and tissues than TFV disoproxil fumarate.

GS-9451 (Vedroprevir) is a potent HCV NS3/4A protease inhibitor with Ki of 0.41 nM, inhibits HCV GT-1b NS3/4A with IC50 of 3.2 nM in enzymatic assays.

GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7(TLR-7) in chimpanzees with chronic HBV infection.

GS-9695 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 1.2 nM..

GS-9973 is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM. Phase 2.

GSA-10 is a novel small-molecule positive modulator of Smoothened with EC50 of 1.2 uM in the differentiation assay.

GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family.

GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase with Ki value of 0.5 nM.

GSK180736A is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM.

GSK1940029 is a stearoyl CoA desaturase 1 inhibitor.

GSK199 is a reversible inhibitor of PAD4 (IC50 = 200 nM) that binds to the low-calcium form of the enzyme and is selective for PAD4 over PAD1-3.

GSK2200150A is an antimycobacterial agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG.

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM, with no activity at other close related AGC-kinases.

GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC50 of 398 nM, p70S6K IC50 of 1000nM), and a dramatically improved P450 profile (>2.2 uM at all isozymes tested).

GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.

GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC50 of 0.9 nM. It is highly selective for PERK with IC50 values >100 nM against a panel of 300 kinases.

GSK2801 is a very potent inhibitor of the BAZ2 family of bromodomain containing proteins.

GSK2814338, also known as Lp-PLA2 -IN-1, is a Lp-PLA2 inhibitor

GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection.

GSK-2894631A,GSK 2894631A，GSK2894631A

GSK3039294 is a Serum amyloid P component inhibitor.

GSK3145095 is an orally available, small-molecule inhibitor of RIPK1, with potential antineoplastic and immunomodulatory activities.

GSK369796 shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain

GSK467 is a potent and selective inhibitor of KDM5 (also known as JARID1). GSK467 exploits unique binding modes.

GSK547 (RIP1i, GSK 547) is a highly selective and potent inhibitor of RIP1 kinase that robustly targets RIP1 in vivo.

GSK-8573 is the inactive control of GSK-2801.

GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1.

GSK9311 is a potent and highly selective inhibitor of the BRPF bromodomain (BRPDF1 pIC50 = 6.0; BRPDF2 pIC50 = 4.3).

GSK-F1 is a potent inhibitor of PI4KA.

GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).

GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1).

GSM-1 (GSM1) is a γ-secretase modulator that directly targets the transmembrane domain (TMD) 1 of presenilin 1, shows potent Aβ42-lowering effect (IC50=0.348 uM) in a cell-based assay.

GSM-2 is a second-generation γ-secretase modulator (GSM) that only decreases Aβ42 (IC50=65.2 nM), while inversely increasing Aβ38 and having no effect on β-CTF and Aβ40 levels.

GSTO1 inhibitor C1-27 is a potent, selective, covalent glutathione S-transferase omega 1 (GSTO1) inhibitor with IC50 of 31 nM.

GT 949 is a selective excitatory amino acid transporter-2 (EAAT2) positive allosteric modulator with an EC50 of 0.26 nM.

GTC-365 (NSC 177365) is a small drug-like pharmacological chaperone that induces cancer cell death by restoring tertiary DNA structures in mutant human telomerase reverse transcriptase (hTERT) promoters.

GTC-365 (NSC 177365) is a small drug-like pharmacological chaperone that induces cancer cell death by restoring tertiary DNA structures in mutant human telomerase reverse transcriptase (hTERT) promoters.

Guaifenesin(Guaiphenesin)

Guanabenz (WY 8678) is an α2 adrenergic receptor agonist that is used as an antihypertensive agent, also has been proposed to exert protective effects against misfolding by interfering with eIF2α-P dephosphorylation through selective disruption of a PP1-P

Guanidinosuccinic acid is a nitrogenous metabolite isolated in excess from serum and urine.

GUT-70 is a tricyclic coumarin derived from Calophyllum brasiliense, markedly reduces cell proliferation, viability through G1 cell cycle arrest and increases apoptosis.

GV-58 is a potent, selective N-Type and P/Q-type Ca2+ Channel agonist with EC50 of 7.2 and 8.8 uM, shows no acitivity for L-type calcium channels (EC50>100 uM).

GW 275175X is a derivative of BDCRB that displays anti-HCMV activity by inhibition of viral DNA maturation.

GW 841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomain that displays activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia..

GW274150 is a novel arginine-competitive, NADPH-dependent iNOS inhibitor that has been identified from a series of acetamide amino acids that have a high selectivity for iNOS vs both eNOS (> 260-fold) and nNOS (> 219-fold) and high bioavailability (> 90%) after oral administration.Target: iNOSin vivo: GW274150 demonstrates a narrow neuroprotective therapeutic window against the toxic actions of 6-OHDA. GW274150 administration leads to a dose-dependent decrease in the number of iNOS-positive cells in the SNc of the 6-OHDA-lesioned animals. The iNOS inhibitor GW274150 fails to produce long-term neuroprotection after its withdrawal in the 6-OHDA-lesioned rat. [1]

GW311616A is a potent, intracellular human neutrophil elastase (HNE, α-1-proteinase) inhibitor.

GW406108X (GW-406108X, GW108X) is specific inhibitor of Kif15 (Kinesin-12) with IC50 of 0.82 uM in ATPase assays.

GW4869 is a cell permeable, selective inhibitor of N-SMase (neutral sphingomyelinase).

GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist with pKi of 7.86 for inhibiting eotaxin-induced eosinophil chemotaxis in vitro assays.

GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist with pKi of 7.86 for inhibiting eotaxin-induced eosinophil chemotaxis in vitro assays.

GW-8510 (GW8510) is a potent, selective inhibitor of CDK2 with IC50 of 10 nM.

GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32.

GX-674 is a potent, selective Nav1.7 inhibitor with IC50 of 0.1 nM.

GX-936 (PF 05196233) is a potent Nav1.7 inhibitor that binds to the activated state of voltage-sensor domain IV (VSD4), exhibits robust inhibition of the 1KαPMTX-evoked N1742K response with IC50 of 40 nM.

GYY 4137 is a Water-soluble, slow-releasing hydrogen sulfide donor.

GZ389988 (GZ-389988) is a novel potent, selective, locally delivered TrkA inhibitor for the treatment osteoarthritis.

GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

GZD856 is a novel and orally bioavailable PDGFRα/β inhibitor with IC50s of 68.6 and 136.6 nM, respectively. Anti-lung cancer activities. Also a Bcr-AblT315I inhibitor with IC50s of 19.9 and 15.4 nM for Bcr-Abl and T315I mutant.

H3B8800 is an orally available splicing modulator that targets spliceosome SF3b complex containing either WT or mutant SF3B1 (binding IC50 of 0.3-2 nM),demonstrates dose-dependent inhibition of both canonical splicing and aberrant splicing induced by mutant SF3B1 in in vitro assays of biochemical splicing, induces lethality in spliceosome-mutant cancer cells.. H3B-8800 potently and preferentially kills spliceosome-mutant epithelial and hematologic tumor cells.

H4R antagonist 1

HA15 displayed anti-cancerous activity on all melanoma cells tested, including cells isolated from patients and cells that developed resistance to BRAF inhibitors.

Halcinonide is a high potency corticosteroid used topically in the treatment of certain skin conditions.

Halofuginone is the competitively inhibitor of prolyl-tRNA synthetase with Ki of 18.3 nM.It could also down-regulate Smad3 and blocked TGF-β signaling at 10 ng/ml in mammal.

Haloperidol (Haldol)

HAMNO is a novel protein interaction inhibitor of replication protein A (RPA).

HAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM..

HAR-171 is a small molecule gp120-CD40 blocker that acts as a highly potent HIV entry inhibitor with IC50 of 0.43 uM against YTA48P virus with no significant cytotoxicity (CC50>120 uM)..